Zoll Medical Corp., of Chelmsford, Mass., received CE mark approval to market its second-generation Supersaturated Oxygen (SSO2) Therapy in Europe and other countries that accept CE mark. The therapy, which delivers hyperbaric levels of oxygen to the ischemic heart muscle immediately following percutaneous coronary intervention, has been shown to significantly reduce damage to the heart muscle after an acute myocardial infarction. "SSO2 Therapy will support clinicians in delivering the highest quality of care for their [ST-elevation myocardial infarction] patients in Europe and other countries that accept CE mark," said Neil Johnston, president, Zoll Circulation. Continue reading →

The Fourth Universal Definition ofMyocardial Infarction(FUDMI) [published simultaneously in 2018 in numerous journals including Circulation, Journal of the American College of Cardiology and European Heart Journal] focuses mainly on the distinction between non-ischemicmyocardialinjury andmyocardial infarction(MI), along with the role of cardiovascular magnetic resonance, in order to define the etiology ofmyocardialinjury. Continue reading →

Myocardial Infarction Drugs Market analysis report has recently added by HealthCare Intelligence Markets which helps to make informed business decisions. This research report further identifies the market segmentation along with their sub-types. The Global Myocardial Infarction Drugs Market is expected to reach a huge CAGR during the forecast period. Continue reading →

Transparency Market Research (TMR) has published a new report titled, Anticoagulants Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026. According to the report, theglobal anticoagulants marketwas valued at US$ 21,759.3 Mn in 2018 and is projected to expand at a CAGR of 8.0% from 2018 to 2026. Continue reading →

The scope of the Report: The report analyzes the key opportunities, CAGR, and Y-o-Y growth rates to allow readers to understand all the qualitative and quantitative aspects of the Myocardial Infarction Drug market. Continue reading →

It provides the Myocardial Infarction Treatment industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). A recently published report Myocardial Infarction Treatment Market 2020 is a detailed analogy that gives readers insight into the complexity of various factors such as growth rates, technological advances and impacts of socio-economic conditions that affect the marketplace. Continue reading →

OBJECTIVES: To assess the impact of different types of anemia and of concomitant non-cardiovascular chronic illnesses on outcomes of patients with ST-segment elevationmyocardial infarction(STEMI) and baseline anemia admitted to the Intensive Cardiac Care Unit. Based on the mean corpuscular volume, anemia was stratified into: microcytic ( Continue reading →

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today it has received CE Mark approval to market and distribute its SuperSaturated Oxygen (SSO2) Therapy System in Europe. SSO2 Therapy provides interventional cardiologists with the first and only clinically proven treatment beyond percutaneous coronary intervention (PCI) to significantly reduce muscle damage in heart attack patients.1 SSO2 Therapy will support clinicians in delivering the highest quality of care for their STEMI patients in Europe and other countries that accept CE Mark, said Neil Johnston, President, ZOLL Circulation Continue reading →

With much of the medical world focusing on the COVID-19 crisis, two new studies on preeclampsia a pregnancy complication characterized by high blood pressure that can quickly progress to organ damage and even death drew relatively little attention. But those studies contain critically important findings relevant to women at all stages of pregnancy and for the clinicians who care for them. Continue reading →

Up-titration to high-intensity statins early on in the course of treatment was found to be associated with a lower risk for cardiovascular (CV) events compared with no up-titration in patients at very high risk for CV disease, according to a study published in the European Heart Journal Quality Care and Clinical Outcomes. The data of 192,435 patients (ages, 18 years; mean age, 68 years) from a Swedish national population-based registry database were retrospectively examined. Patients in this cohort were at very high risk for atherosclerotic CV disease according to European Society of Cardiology guideline definitions and had initiated moderate-intensity stating therapy between 2006 and 2013. Continue reading →